Sofosbuvir: A new oral once-daily agent for the treatment of hepatitis C virus infection

P and T

Volumn 39, Issue 5, 2014, Pages 345-352

  Cha, Agnes ^a   Budovich, Aliaksandr ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DACLATASVIR; LEDIPASVIR; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MIXED INFECTION; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SUSTAINED VIROLOGIC RESPONSE;

EID: 84901387797     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013:159(5):349-357.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
3. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: An estimate of true prevalence. Liver Int 2011;31:1090-1101.
4. Hoofnagle J, Di Bisceglie A. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
5. McHutchison J, Gordon S, Schiff E, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
6. Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
7. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
8. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-1718.
9. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777.
10. Sovaldi [package insert]. Foster City, California: Gilead Sciences, Inc.; 2013.
11. Statement on a nonproprietary name adopted by the USAN Council. Available at: http://www.ama-assn.org/resources/doc/usan/sofosbuvir.pdf. Accessed on May 3, 2013.
12. Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis C virus NS5B RNAdependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997;71(11):8416-8428.
13. Sofia M, Bao D, Chang W, et al. Discovery of a β-D-2́-deoxy-2́-a-fluoro-2́-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53:7202-7218.
14. Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010;285(45):34337-34347.
15. Dinning J, Cornpropst M, Flach S, et al. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus following single ascending doses in healthy subjects. Antimicrob Agents Chemother 2013;57(3):1201-1208.
16. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58(3):583-592.
17. Lam A, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56(6):3359-3368.
18. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Cl Ga 2012;26:487-503.
19. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-1887.
20. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 on patients without treatment options. N Engl J Med 2013;368(20):1867-1877.
21. Gilead Sciences, Inc. Gilead announces new sustained viral response data for sofosbuvir-based regimens in genotype 3-infected hepatitis C patients [Press release]. 2013. Available at: http://www.gil-ead.com/news/press-releases/2013/11/gilead-announces-new-sustained-viral-response-data-for-sofosbuvirbased-regi-mens-in-genotype-3infected-hepatitis-c-patients. Accessed April 2, 2014.
22. Kowdley KV, Hassanein T, Gane EJ, et al. Sofosbuvir safety and tolerability in 778 patients treated for up to 24 weeks in four phase 2 studies. European Association for the Study of the Liver (EASL), 48th annual meeting, April 24-28, 2013, Amsterdam. Available at: www.natap.org/2013/EASL/EASL_64.htm. Accessed Setpember 7, 2013.
23. Gilead Sciences, Inc. Gilead announces phase 3 results for an all-oral, sofosbuvir-based regimen for the treatment of hepatitis C in patients co-infected with HIV [Press release]. 2013. Available at: http://www.gilead.com/news/pressreleases/2013/11/gilead-announcesphase-3-results-for-an-alloral-sofosbuvirbased-regimen-for-the-treatment-of-hepatitis-c-in-patients-coinfected-with-hiv. Accessed April 2, 2014.
24. Gilead Sciences, Inc. Gilead announces phase 2 results for sofosbuvir-based regimens in hepatitis C patients before and after liver transplantation [Press release]. 2013. Available at: http://www.gilead.com/news/press-releases/2013/11/gilead-announces-phase-2-results-for-sofosbuvirbased-regimens-in-hepatitis-c-patients-before-and-after-liver-transplantation. Accessed April 2, 2014.
25. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. Hepatology: Special Issue: The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013. 2013;58(4):1379A.
26. Lawitz E et al. Simeprevir plus sofosbuvir with/without ribavirin in HCVgenotype 1 prior null-responder/treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with metavir F3-4 (cohort 2). 49th Annual Meeting of the European Association for the Study of the Liver, abstract O165, London, 2014.
27. Infectious Diseases Society of America (IDSA) and American Association for the Study of Liver Diseases (AASLD). Recommendations for Testing, Managing, and Treating Hepatitis C. 2013. Available at: www.hcvguidelines.org/fullreport. Accessed April 2, 2014.
28. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virological response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) (Abstract 1417). European Association for the Study of the Liver (EASL), 48th annual meeting, April 24-28, 2013, Amsterdam. Available at: www.natap.org/2013/EASL/EASL_22.htm. Accessed September 7, 2013.
29. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370(16):1483-1493.
30. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med April 12, 2014. doi: 10.1056/NEJMoa1402454.
31. Kowdley K, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med April 11, 2014. doi: 10.1056/ NEJMoa1402355.
32. Red Book Online. Ann Arbor, Michigan; Truven Health Analytics. Accessed April 16, 2014.
33. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology 2014;59(4):1246-1249.